Anika Therapeutics (Anika Therapeutics) GF Value : $29.76 (As of Apr. 29, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-29), Anika Therapeutics's share price is $26.06. Anika Therapeutics's GF Value is $29.76. Therefore, Anika Therapeutics's Price-to-GF-Value for today is 0.88.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Anika Therapeutics is Modestly Undervalued.

Anika Therapeutics (NAS:ANIK) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Anika Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	26.06	/	29.76
	=	0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics (Anika Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Anne Nunes	officer: SVP, Chief Operations Officer	32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti	director	600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran	officer: EVP, General Counsel, Corp Sec	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz	officer: EVP, CFO, Treasurer	C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land	director
Stephen Richard	director	C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop	officer: EVP Business Development	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung	officer: CFO	ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson	director	1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling	officer: President	501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767